These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

804 related articles for article (PubMed ID: 30385782)

  • 1. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
    Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
    Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous oligodendroglial alpha-synuclein and TPPP/p25α orchestrate alpha-synuclein pathology in experimental multiple system atrophy models.
    Mavroeidi P; Arvanitaki F; Karakitsou AK; Vetsi M; Kloukina I; Zweckstetter M; Giller K; Becker S; Sorrentino ZA; Giasson BI; Jensen PH; Stefanis L; Xilouri M
    Acta Neuropathol; 2019 Sep; 138(3):415-441. PubMed ID: 31011860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of the novel A53E alpha-synuclein mutation on its oligomerization and aggregation.
    Lázaro DF; Dias MC; Carija A; Navarro S; Madaleno CS; Tenreiro S; Ventura S; Outeiro TF
    Acta Neuropathol Commun; 2016 Dec; 4(1):128. PubMed ID: 27938414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prominent astrocytic alpha-synuclein pathology with unique post-translational modification signatures unveiled across Lewy body disorders.
    Altay MF; Liu AKL; Holton JL; Parkkinen L; Lashuel HA
    Acta Neuropathol Commun; 2022 Nov; 10(1):163. PubMed ID: 36371251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain.
    Svarcbahs R; Julku UH; Myöhänen TT
    J Neurosci; 2016 Dec; 36(49):12485-12497. PubMed ID: 27927963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endosulfine-alpha inhibits membrane-induced α-synuclein aggregation and protects against α-synuclein neurotoxicity.
    Ysselstein D; Dehay B; Costantino IM; McCabe GP; Frosch MP; George JM; Bezard E; Rochet JC
    Acta Neuropathol Commun; 2017 Jan; 5(1):3. PubMed ID: 28069058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transgenic Mice Expressing Human α-Synuclein in Noradrenergic Neurons Develop Locus Ceruleus Pathology and Nonmotor Features of Parkinson's Disease.
    Butkovich LM; Houser MC; Chalermpalanupap T; Porter-Stransky KA; Iannitelli AF; Boles JS; Lloyd GM; Coomes AS; Eidson LN; De Sousa Rodrigues ME; Oliver DL; Kelly SD; Chang J; Bengoa-Vergniory N; Wade-Martins R; Giasson BI; Joers V; Weinshenker D; Tansey MG
    J Neurosci; 2020 Sep; 40(39):7559-7576. PubMed ID: 32868457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FTY720-Mitoxy reduces synucleinopathy and neuroinflammation, restores behavior and mitochondria function, and increases GDNF expression in Multiple System Atrophy mouse models.
    Vidal-Martinez G; Segura-Ulate I; Yang B; Diaz-Pacheco V; Barragan JA; De-Leon Esquivel J; Chaparro SA; Vargas-Medrano J; Perez RG
    Exp Neurol; 2020 Mar; 325():113120. PubMed ID: 31751571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α-Synuclein Insult.
    Henderson MX; Sedor S; McGeary I; Cornblath EJ; Peng C; Riddle DM; Li HL; Zhang B; Brown HJ; Olufemi MF; Bassett DS; Trojanowski JQ; Lee VMY
    Neuron; 2020 Mar; 105(5):822-836.e7. PubMed ID: 31899072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of alpha synuclein disrupts APP and Endolysosomal axonal trafficking in a mouse model of synucleinopathy.
    Lin S; Leitão ADG; Fang S; Gu Y; Barber S; Gilliard-Telefoni R; Castro A; Sung K; Shen R; Florio JB; Mante ML; Ding J; Spencer B; Masliah E; Rissman RA; Wu C
    Neurobiol Dis; 2023 Mar; 178():106010. PubMed ID: 36702318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-synuclein pathology, microgliosis, and parvalbumin neuron loss in the amygdala associated with enhanced fear in the Thy1-aSyn model of Parkinson's disease.
    Torres ERS; Stanojlovic M; Zelikowsky M; Bonsberger J; Hean S; Mulligan C; Baldauf L; Fleming S; Masliah E; Chesselet MF; Fanselow MS; Richter F
    Neurobiol Dis; 2021 Oct; 158():105478. PubMed ID: 34390837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ɑ-Synuclein strains and seeding in Parkinson's disease, incidental Lewy body disease, dementia with Lewy bodies and multiple system atrophy: similarities and differences.
    Peelaerts W; Bousset L; Baekelandt V; Melki R
    Cell Tissue Res; 2018 Jul; 373(1):195-212. PubMed ID: 29704213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies.
    Koob AO; Ubhi K; Paulsson JF; Kelly J; Rockenstein E; Mante M; Adame A; Masliah E
    Exp Neurol; 2010 Feb; 221(2):267-74. PubMed ID: 19944097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ⍺-Synuclein Structural Diversity and the Cellular Environment in ⍺-Synuclein Transmission Models and Humans.
    Peelaerts W; Baekelandt V
    Neurotherapeutics; 2023 Jan; 20(1):67-82. PubMed ID: 37052776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies.
    Price DL; Rockenstein E; Mante M; Adame A; Overk C; Spencer B; Duong-Polk KX; Bonhaus D; Lindsey J; Masliah E
    Sci Rep; 2016 Jul; 6():29523. PubMed ID: 27389831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein.
    Bernis ME; Babila JT; Breid S; Wüsten KA; Wüllner U; Tamgüney G
    Acta Neuropathol Commun; 2015 Nov; 3():75. PubMed ID: 26612754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein α-synuclein.
    Wang W; Nguyen LT; Burlak C; Chegini F; Guo F; Chataway T; Ju S; Fisher OS; Miller DW; Datta D; Wu F; Wu CX; Landeru A; Wells JA; Cookson MR; Boxer MB; Thomas CJ; Gai WP; Ringe D; Petsko GA; Hoang QQ
    Proc Natl Acad Sci U S A; 2016 Aug; 113(34):9587-92. PubMed ID: 27482083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson's disease, multiple system atrophy and dementia with Lewy bodies.
    Van der Perren A; Gelders G; Fenyi A; Bousset L; Brito F; Peelaerts W; Van den Haute C; Gentleman S; Melki R; Baekelandt V
    Acta Neuropathol; 2020 Jun; 139(6):977-1000. PubMed ID: 32356200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation.
    Lázaro DF; Rodrigues EF; Langohr R; Shahpasandzadeh H; Ribeiro T; Guerreiro P; Gerhardt E; Kröhnert K; Klucken J; Pereira MD; Popova B; Kruse N; Mollenhauer B; Rizzoli SO; Braus GH; Danzer KM; Outeiro TF
    PLoS Genet; 2014 Nov; 10(11):e1004741. PubMed ID: 25393002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.
    Spillantini MG; Goedert M
    Ann N Y Acad Sci; 2000; 920():16-27. PubMed ID: 11193145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.